MOR 202

Drug Profile

MOR 202

Alternative Names: MOR-03087; MOR202

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator MorphoSys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Leukaemia

Most Recent Events

  • 17 Oct 2016 Interim adverse events and efficacy data from a phase I/II trial in Multiple myeloma released by MorphoSys
  • 06 Jun 2016 Efficacy data from a phase I/II trial in Multiple myeloma presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2016)
  • 07 Dec 2015 Interim efficacy and adverse events data from a phase I/IIa trial in Multiple myeloma presented at the Annual Society of hematology (ASH-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top